Although a series of molecular targets have been investigated in clinical trials, only HER2-targeted trastuzumab [1] and immune checkpoint inhibitors (e.g., pembrolizumab or nivolumab) demonstrated feasible response rates and have been documented as standard first-line therapies for advanced GC [2–4]. The gene discussed is ERBB2; the disease is gastric cancer.